Bristol Myers Squibb Co. (BMY)
61.48
-1.52
(-2.41%)
USD |
NYSE |
Oct 23, 16:00
61.49
+0.01
(+0.02%)
Pre-Market: 20:00
Bristol Myers Squibb Enterprise Value : 159.59B for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 159.59B |
| October 22, 2026 | 162.70B |
| October 21, 2026 | 158.85B |
| October 20, 2026 | 160.00B |
| October 19, 2026 | 154.18B |
| October 16, 2026 | 156.06B |
| October 15, 2026 | 157.73B |
| October 14, 2026 | 155.10B |
| October 13, 2026 | 149.76B |
| October 12, 2026 | 151.62B |
| October 09, 2026 | 154.77B |
| October 08, 2026 | 155.71B |
| October 07, 2026 | 155.95B |
| October 06, 2026 | 155.73B |
| October 05, 2026 | 154.13B |
| October 02, 2026 | 158.92B |
| October 01, 2026 | 159.55B |
| September 30, 2026 | 161.47B |
| September 29, 2026 | 162.41B |
| September 28, 2026 | 164.49B |
| September 25, 2026 | 162.41B |
| September 24, 2026 | 159.63B |
| September 23, 2026 | 158.92B |
| September 22, 2026 | 161.16B |
| September 21, 2026 | 161.92B |
| Date | Value |
|---|---|
| September 18, 2026 | 162.82B |
| September 17, 2026 | 162.37B |
| September 16, 2026 | 163.92B |
| September 15, 2026 | 164.19B |
| September 14, 2026 | 164.94B |
| September 11, 2026 | 164.00B |
| September 10, 2026 | 164.23B |
| September 09, 2026 | 165.58B |
| September 08, 2026 | 166.15B |
| September 04, 2026 | 170.50B |
| September 03, 2026 | 173.09B |
| September 02, 2026 | 172.22B |
| September 01, 2026 | 170.70B |
| August 31, 2026 | 170.48B |
| August 28, 2026 | 170.01B |
| August 27, 2026 | 170.76B |
| August 26, 2026 | 172.03B |
| August 25, 2026 | 172.75B |
| August 24, 2026 | 171.44B |
| August 21, 2026 | 170.89B |
| August 20, 2026 | 167.74B |
| August 19, 2026 | 172.11B |
| August 18, 2026 | 168.93B |
| August 17, 2026 | 166.03B |
| August 14, 2026 | 164.39B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Johnson & Johnson | 662.44B |
| Eli Lilly & Co. | 1.245T |
| Merck & Co., Inc. | 405.39B |
| Pfizer Inc. | 222.94B |
| AstraZeneca PLC | 558.20B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 3.316B |
| Revenue (Quarterly) | 12.98B |
| Total Expenses (Quarterly) | 9.665B |
| EPS Diluted (Quarterly) | 1.620 |
| Gross Profit Margin (Quarterly) | 67.95% |
| Profit Margin (Quarterly) | 25.54% |
| Earnings Yield | 7.38% |
| Operating Earnings Yield | 12.67% |
| Normalized Earnings Yield | 9.991 |